Abstract：Objective: To explore the approaches for a clinical pharmacist participating in pharmaceutical care for adverse reactions after chemotherapy. Methods: Clinical pharmacists involved in the treatment of diarrhea and febrile neutropenia in one patient with oral squamous cell carcinoma after TPF neoadjuvant chemotherapy was analyzed descriptively.Results: Clinical pharmacists assisted physicians to develop individualized treatment protocol according to the relevant guidelines to improve patient condition. Conclusion: Clinical pharmacist should participate in the healthcare team and conduct pharmaceutical care to reduce the incidence of serious adverse reactions in patients.
毛棉，蒋刚. 临床药师对1 例口腔癌新辅助化疗的药学监护[J]. 临床药物治疗杂志, 2017, 15(3): 82-81.
MAO Mian, JIANG Gang. Pharmaceutical care for a patient with mouth neoplasms after neoadjuvant chemotherapy. CLINICAL MEDICATION JOURNAL, 2017, 15(3): 82-81.
[1] Weems D H, Mendenhall W M, Parsons J T, et al. Squamous cell carcinoma of the supraglottic larynx treatedwith surgery and/or radiation therapy[J].Int J Radiat Oncol Biol Phys, 1987, 13(10):1483-1487.
[2] Su X Y, Zheng J W, Zheng G S, et al. Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma:a metaanalysis[J].Chin Med J(Engl), 2008, 121(19):1939-1944.
[3] Blanchard P, Bourhis J, Lacas B, et al. Taxane-Cisplatin-Fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group[J]. J Clin Oncol,2013, 31(23):2854-2860.
[4] 郭海鹏, 刘木元, 杨熙鸿, 等，新辅助化疗对口腔癌生存率影响的Meta 分析[J]. 汕头大学医学院学报, 2014, 27(2):100-103.
[5] Takácsi-Nagy Z, Hitre E, Remenár é, et al. Docetaxel,cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III–IV unresectable head and neck cancer[J]. Strahlenther Onkol, 2015,191(8):635-641.
[6] Vermorken J B, Remenar E, Herpen C V, et al. Cisplatin, Fluorouracil,and Docetaxel in Unresectable Head and Neck Cancer[J].N Engl J Med, 2007, 357(17):1695-704.
[7] Posner M R, Hershock D M, Blajman C R, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer[J]. N Engl J Med, 2007, 357(17):1705-1715.
[8] Peterson D E.Pretreatment strategies for infection prevention in chemotherapy patients[J].NCI Monogr, 1990, 9(9):61-71.
[9] 周际昌. 实用肿瘤内科学[M]. 北京: 人民卫生出版社, 1999, 23.
[10] 刘新春, 程玉峰. 实用抗肿瘤药物治疗学[M]. 北京: 人民卫生出版社, 2002:1075.
[11] Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer Chemotherapy[J].Lancet Oncol, 2014，15(10):447-460.
[12] Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase Biochemical basis for familial pyrimidinemia and severe 5-fl uorouracil-induced toxicity[J]. J Clin Invest, 1988, 81(1): 47-51.
[13] 中华医学会血液学分会、中国医师协会血液科医师分会. 2012 年中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南[J]. 中华血液学杂志, 2012, 33(8): 693-696．
[14] Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al．Mortality,length of stay,and cost associated with hospitalized adult cancer patients with febrile neutropenia[J].Asian Pac J Cancer Prev, 2013,14(2):1115-1119.
[15] Freifeld A G, Bow E J, Sepkowitz K A, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the infectious diseases society of america[J].Clin Infect Dis, 2011, 52(4):e56-93.
[16] Flowers C R, Seidenfeld J, Bow E J, et al. Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy:American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2013, 31(6):794-810.
2017, Vol. 15 
